Incyte Corporation (Nasdaq: INCY) announced today that it has entered into a clinical trial collaboration agreement with Merck, through a Merck subsidiary, to evaluate the safety and efficacy of Incyte's oral indoleamine dioxygenase-1 ...
Tags: collaboration agreement, Incyte's oral indoleamine dioxygenase-1, IDO1